GH Research PLC (GHRS)
NASDAQ: GHRS · Real-Time Price · USD
8.10
+0.04 (0.50%)
Oct 29, 2024, 4:00 PM EDT - Market closed

Company Description

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders.

It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).

The company’s lead program is GH001, an inhalable mebufotenin product candidate, currently under Phase 2b clinical trial for the treatment of patients with TRD, as well as Phase 2a clinical trials for the treatment of Bipolar II disorder and postpartum depression.

It is also involved in the development of GH002, an intravenous mebufotenin product candidate for IV administration, currently under Phase 1 clinical trials for the treatment of psychiatric or neurological disorder; and GH003, an intranasal mebufotenin product candidate for nasal administration, which is currently in preclinical development with a focus on psychiatric and neurological disorders.

The company was founded in 2018 and is based in Dublin, Ireland.

GH Research PLC
GH Research logo
Country Ireland
Founded 2018
IPO Date Jun 25, 2021
Industry Biotechnology
Sector Healthcare
Employees 49
CEO Velichka Valcheva

Contact Details

Address:
Joshua Dawson House, Dawson Street
Dublin, D02 RY95
Ireland
Phone 353 1 437 8334
Website ghres.com

Stock Details

Ticker Symbol GHRS
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $16.00
CIK Code 0001855129
CUSIP Number G3855L106
ISIN Number IE000GID8VI0
SIC Code 2834

Key Executives

Name Position
Dr. Velichka Valcheva M.D. Chief Executive Officer
Florian Schonharting M.Sc. (Econ) Co-Founder and Non-Executive Chairman of the Board
Magnus Halle Co-Founder and MD of Ireland
Julie Ryan F.C.A. Vice President of Finance
Aaron Cameron M.B.A. Chief Operating Officer

Latest SEC Filings

Date Type Title
Sep 20, 2024 6-K Report of foreign issuer
Sep 16, 2024 6-K Report of foreign issuer
Sep 9, 2024 6-K Report of foreign issuer
Sep 3, 2024 6-K Report of foreign issuer
Sep 3, 2024 6-K Report of foreign issuer
Sep 3, 2024 6-K Report of foreign issuer
Jun 28, 2024 6-K Report of foreign issuer
Jun 24, 2024 6-K Report of foreign issuer
May 15, 2024 6-K Report of foreign issuer
May 3, 2024 6-K Report of foreign issuer